Concepedia

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study

Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank, Pietro Andreoné, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Morozov Viacheslav,

Journal of Hepatology · 2022 · 32 citations · 0 references

DOI

Concepts